Pharvaris prices $175 million public offering at $20 per share

Pharvaris N.V. (NASDAQ: PHVS) announced the pricing of an underwritten public offering consisting of 8.25 million ordinary shares at $20.00 per share and pre-funded warrants to purchase 500,000 ordinary shares at $19.99 per warrant to one investor.

The biopharmaceutical company expects to receive approximately $175 million in gross proceeds before deducting underwriting discounts, commissions and offering expenses. Pharvaris has granted underwriters a 30-day option to purchase up to an additional 1.31 million ordinary shares at the public offering price.

The offering is expected to close on or about July 24, 2025, subject to customary closing conditions. Morgan Stanley, Leerink Partners, Cantor, Oppenheimer & Co., and Van Lanschot Kempen are serving as joint book-running managers.

Pharvaris develops oral bradykinin B2 receptor antagonists for bradykinin-mediated diseases including hereditary angioedema and acquired angioedema due to C1 inhibitor deficiency. The company is conducting two pivotal Phase 3 studies for its drug candidate deucrictibant: CHAPTER-3 for prevention of hereditary angioedema attacks and RAPIDe-3 for on-demand treatment.

The shares and pre-funded warrants are being offered pursuant to an effective shelf registration statement previously filed with the Securities and Exchange Commission. The information is based on a company press release.

You May Also Be Interested In

• Caring Brands closes initial $4.6M of $9M private placement
• Energy Vault’s 100 MW AI Infrastructure Project in Sardinia Receives Italian Government Designation as Project of Pre-Eminent National Strategic Interest
• Calix names Juergen Lindner as chief marketing officer